Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2020

Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2020, provides an overview of the Non-Alcoholic Steatohepatitis (Gastrointestinal) pipeline landscape.

Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarring of the liver, which leads to cirrhosis. Symptoms of NASH include fatigue, weight loss for no clear reason, general weakness and an ache in the upper right part of belly. Risk factors include obesity, type 2 diabetes, high cholesterol and high triglycerides and metabolic syndrome.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Alcoholic Steatohepatitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis (NASH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 62, 51, 1, 8, 175, 70 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 7 and 1 molecules, respectively.

Non-Alcoholic Steatohepatitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis (Gastrointestinal).The pipeline guide reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.The pipeline guide reviews key companies involved in Non-Alcoholic Steatohepatitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.The pipeline guide evaluates Non-Alcoholic Steatohepatitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis (Gastrointestinal)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.Find and recognize significant and varied types of therapeutics under development for Non-Alcoholic Steatohepatitis (Gastrointestinal).Classify potential new clients or partners in the target demographic.Develop tactical initiatives by understanding the focus areas of leading companies.Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.Formulate corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Non-Alcoholic Steatohepatitis (NASH) - Overview
Non-Alcoholic Steatohepatitis (NASH) - Therapeutics Development
Non-Alcoholic Steatohepatitis (NASH) - Therapeutics Assessment
Non-Alcoholic Steatohepatitis (NASH) - Companies Involved in Therapeutics Development
Non-Alcoholic Steatohepatitis (NASH) - Drug Profiles
Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects
Non-Alcoholic Steatohepatitis (NASH) - Discontinued Products
Non-Alcoholic Steatohepatitis (NASH) - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by 89bio Inc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by ABIONYX Pharma SA, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Abivax SA, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Abliva AB, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Acquist Therapeutics, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by AdAlta Ltd, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Afimmune Biopharma Ltd, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Akero Therapeutics Inc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Albireo Pharma Inc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Aldeyra Therapeutics Inc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Algernon Pharmaceuticals Inc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Aligos Therapeutics Inc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Allergan Ltd, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Allysta Pharmaceuticals Inc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Alnylam Pharmaceuticals Inc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Altavant Sciences Inc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Altay Therapeutics Inc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Alteogen Inc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Altimmune Inc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Amgen Inc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Angion Biomedica Corp, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by AptaBio Therapeutics Inc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by AptamiR Therapeutics Inc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Araim Pharmaceuticals Inc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Arcturus Therapeutics Ltd, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Arkay Therapeutics LLC, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Terns Pharmaceuticals Inc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by TES Pharma SRL, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Theratechnologies Inc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Thetis Pharmaceuticals LLC, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Thoth Science Inc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Tiziana Life Sciences Plc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by TRACON Pharmaceuticals Inc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by TreeFrog Therapeutics SAS, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Twoxar Inc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Valin Technologies Ltd, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Vascular Biogenics Ltd, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Vectus Biosystems Ltd, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Venenum Biodesign LLC, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Venn Therapeutics LLC, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Verlyx Pharma Inc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Vidasym Inc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Viking Therapeutics Inc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Viscient Biosciences LLC, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Visionary Pharmaceuticals Inc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Vivus Inc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by vTv Therapeutics Inc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Wave Life Sciences Ltd, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Xenexus Pharmaceuticals Pty Ltd, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Xfibra Inc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by XORTX Therapeutics Inc, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by YD Life Science Co, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Yuhan Corp, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Zebra Discovery Ltd, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Zhejiang Doer Biologics Corp, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects, H2 2020
Non-Alcoholic Steatohepatitis (NASH) - Discontinued Products, H2 2020
List of Figures
Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook